What is he best known for?
The fields of study he is best known for:
Fred D. Ledley mainly focuses on Molecular biology, Gene, Genetic enhancement, Biochemistry and Phenylalanine hydroxylase.
His Molecular biology study combines topics from a wide range of disciplines, such as genomic DNA, Genetics, Methylmalonyl-CoA mutase, Expression vector and Polymerase chain reaction.
His work investigates the relationship between Methylmalonyl-CoA mutase and topics such as Open reading frame that intersect with problems in Mutase.
The concepts of his Genetic enhancement study are interwoven with issues in DNA, Clinical trial, Recombinant DNA and Somatic cell.
His work in Biochemistry addresses subjects such as Cholera toxin, which are connected to disciplines such as Sialic acid, Thyrotropin receptor, Hormone and Ganglioside.
His Phenylalanine hydroxylase research integrates issues from Protein primary structure, Phenylketonurias and Mutant.
His most cited work include:
- Nonviral Gene Therapy: The Promise of Genes as Pharmaceutical Products (511 citations)
- Mouse hepatocytes migrate to liver parenchyma and function indefinitely after intrasplenic transplantation. (333 citations)
- Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase (270 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Molecular biology, Gene, Genetics, Genetic enhancement and Biochemistry.
His Molecular biology research is multidisciplinary, incorporating elements of Recombinant DNA, Methylmalonyl-CoA mutase, Phenylalanine hydroxylase, Complementary DNA and Locus.
His Recombinant DNA research incorporates elements of Retrovirus and Transfection.
His studies in Complementary DNA integrate themes in fields like Amino acid and Nucleic acid sequence.
Fred D. Ledley regularly links together related areas like Pharmacology in his Gene studies.
His research investigates the link between Genetic enhancement and topics such as Pathology that cross with problems in Transplantation.
He most often published in these fields:
- Molecular biology (38.60%)
- Gene (24.65%)
- Genetics (22.79%)
What were the highlights of his more recent work (between 2010-2021)?
- Translational science (3.26%)
- Maturity (2.79%)
- Initial public offering (2.33%)
In recent papers he was focusing on the following fields of study:
Translational science, Maturity, Initial public offering, Biotechnology and Nih funding are his primary areas of study.
His research investigates the connection between Translational science and topics such as Drug development that intersect with problems in Drug discovery.
He has researched Maturity in several fields, including Genetic enhancement and Knowledge management.
While the research belongs to areas of Knowledge management, he spends his time largely on the problem of Emergent disease, intersecting his research to questions surrounding Clinical trial.
His research in Biotechnology intersects with topics in New product development and Net asset value.
In his study, Public health is inextricably linked to Economic growth, which falls within the broad field of Nih funding.
Between 2010 and 2021, his most popular works were:
- Contribution of NIH funding to new drug approvals 2010–2016 (69 citations)
- Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies (27 citations)
- Patterns of technological innovation in biotech. (27 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Translational science, Drug development, Maturity, New product development and Biotechnology.
His Translational science research includes elements of Clinical trial, Drug approval, Pharmacology and Oncology.
He regularly ties together related areas like Internal medicine in his Drug development studies.
As a part of the same scientific family, Fred D. Ledley mostly works in the field of Maturity, focusing on Drug discovery and, on occasion, Amyloid precursor protein, Alzheimer's disease, Neuroscience and Amyloid precursor protein secretase.
The various areas that he examines in his New product development study include Computational biology and Bioinformatics.
His Biotechnology research is multidisciplinary, relying on both Commercialization, Business model, Industrial organization and Genetic enhancement.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
